Yersinia pestis (plague) vaccines

@article{Titball2004YersiniaP,
  title={Yersinia pestis (plague) vaccines},
  author={Richard W. Titball and E. Diane Williamson},
  journal={Expert Opinion on Biological Therapy},
  year={2004},
  volume={4},
  pages={965 - 973}
}
Live attenuated and killed whole cell vaccines against disease caused by Yersinia pestis have been available since the early part of the last century. Although these vaccines indicate the feasibility of protecting against disease, they have a number of shortcomings. The live attenuated vaccine is highly reactogenic and is not licensed for use in humans. The killed whole cell vaccine, also reactogenic, provides poor protection against pneumonic plague and immunisation requires mutiple doses of… Expand
Live-attenuated Yersinia pestis vaccines
TLDR
Current attempts to construct attenuated Y. pestis strains with specifically defined mutations have opened the door for developing new candidates for live-attenuated plague vaccines, with a proper balance between safety and protective efficacy. Expand
Prospects for new plague vaccines
TLDR
The potential application of Yersinia pestis for bioterrorism emphasizes the urgent need to develop more effective vaccines against airborne infection and the present emphasis is on subunit vaccines based on the F1 and LcrV antigens. Expand
Yersinia pestis caf1 Variants and the Limits of Plague Vaccine Protection
TLDR
It is shown here that immunization with live, attenuated strains generates plague-protective immunity and humoral immune responses against F1 pilus antigen and LcrV, in agreement with the notion that LCrV can elicit vaccine protection against both types of virulent plague strains. Expand
Developing live vaccines against Yersinia pestis
Three great plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people and it has been linked to biowarfare in the past. Plague is endemic in manyExpand
Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice.
TLDR
This work developed a novel production and delivery system for a plague vaccine of a Y. pestis F1-V antigen fusion protein expressed in tomato that allowed producing an oral vaccine candidate without protein purification and with minimal processing technology. Expand
CHAPTER 4 Immunological aspects of Y . pestis and vaccines
Plaque vaccines have been used since 1896 and have been found to reduce the incidence and severity of bubonic plague resulting from the bite of infected fleas. Both viable and nonviable plagueExpand
Developing live vaccines against plague.
TLDR
The progress of live attenuated vaccines against plagu is summarized, with a focus on the use of attenuated viral vectors or attenuated Salmonella strains to deliver plague antigens. Expand
Plague vaccines: current developments and future perspectives
TLDR
Current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis are analyzed. Expand
Prevention of bubonic and pneumonic plague using plant-derived vaccines.
TLDR
This review focuses on the recent research accomplishments towards the development of safe and effective pneumonic and bubonic plague vaccines using plants as bioreactors. Expand
Plague Vaccine Development: Current Research and Future Trends
TLDR
The scientific contributions and existing progress in developing subunit vaccines, the role of molecular adjuvants; DNA vaccines; live delivery platforms; and attenuated vaccines developed to counteract virulent strains of Y. pestis are reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
TLDR
This recombinant vaccine, composed of a fusion protein of F1 with a second protective immunogen, V antigen, protected experimental mice against pneumonic as well as bubonic plague produced by either an F1+ or F1- strain of Y. pestis, and may provide the basis for an improved human plague vaccine. Expand
Potency of killed plague vaccines prepared from avirulent Yersinia pestis.
Killed plague vaccines prepared from avirulent strains A1122 and EV76S of Yersinia pestis were more effective in mouse potency tests than samples of Plague Vaccine, USP, prepared from killed Y.Expand
Protective Efficacy of RecombinantYersinia Outer Proteins against Bubonic Plague Caused by Encapsulated and Nonencapsulated Yersinia pestis
TLDR
Vaccination with YpkA significantly prolonged mean survival time but did not increase overall survival of mice infected with the nonencapsulated strain, and the only significant protection against death was observed in YopD-vaccinated mice challenged with theNonencapsulation strain. Expand
A single dose sub-unit vaccine protects against pneumonic plague.
TLDR
The enhanced protective efficacy of this sub-unit vaccine administered as a single dose compared with an existing vaccine has been demonstrated in an outbred animal model of pneumonic plague. Expand
Intranasal vaccination against plague, tetanus and diphtheria.
TLDR
Nano immunisation has been shown favourably effective in small animal models, and a limited number of early phase clinical trails, and adjuvantisation of toxoid/subunit molecules appears to be a requisite for elicitation of appreciable immunological responses, following nasal administration of acellular immunogens. Expand
Effectiveness of live or killed plague vaccines in man.
  • K. F. Meyer
  • Biology, Medicine
  • Bulletin of the World Health Organization
  • 1970
TLDR
The USP formol-killed, virulent Pasteurella pestis (Yersinia pestis) suspension capable of protecting 60% of non-human primates, particularly Hanuman langurs (Presbytis entellus), warrants further clinical tests and field trials. Expand
Plague immunization. I. Past and present trends.
TLDR
The evidence presented in the literature indicates that programs of mass immunization with highly immunogenic, living, attenuated strains of Yersinia pestis are accompanied by harmful side effects. Expand
A new improved sub-unit vaccine for plague: the basis of protection.
TLDR
The limit of protection achievable by immunisation with sub-units of Yersinia pestis against the development of plague in an experimental animal model is determined and the combined sub-unit vaccine has clear advantages over the live vaccine in terms of safety of use and absence of side-effects. Expand
A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model.
TLDR
The relative efficacy of a live attenuated vaccine strain of Y. pestis (EV76) was compared with that of the formaldehyde-killed vaccine (Plague vaccine, USP). Expand
Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.
TLDR
These F1 and V subunit vaccines may offer effective long-term immunity with a reduced dosage schedule when compared with the presently licensed, formalin-killed, whole-cell vaccine. Expand
...
1
2
3
4
5
...